Immunotherapy-Induced Adrenal Insufficiency in Melanoma: Surveillance and Management
Afreen Shariff, MD, MBBS, examines the surveillance and management of immunotherapy-induced adrenal insufficiency in the context of melanoma, underscoring the importance of maintaining a heightened awareness for early detection.
EP: 1.An Overview of the Landscape Surrounding Melanoma
EP: 2.The Role of Biomarker Testing in Melanoma
EP: 3.The Current Landscape Surrounding Adjuvant Therapy in Melanoma
EP: 4.Combination Immunotherapy Strategies for Melanoma in the Adjuvant Setting
EP: 5.Navigating Challenges in Predicting and Mitigating Adverse Events in Adjuvant Immunotherapy
EP: 6.Exploring Immunotherapy Resistance: Impact on Treatment Decisions in Melanoma
EP: 7.Balancing Quality of Life: Adjuvant Therapy Toxicity in Melanoma Adjuvant Immunotherapy
EP: 8.Case 1: Man Aged 55 Years With Stage IIIB Melanoma Developing Immunotherapy-Induced Diabetes
EP: 9.Immunotherapy-Related Diabetes in Melanoma: A Management Perspective
EP: 10.Immunotherapy-Induced Adrenal Insufficiency in Melanoma: Surveillance and Management
EP: 11.Case 2: 63-Year-Old Female Patient With Metastatic Melanoma on Dual Immunotherapy Developing Treatment-Related Myocarditis
EP: 12.Approaches to Diagnosing and Managing Myocarditis Related to Immunotherapy
EP: 13.Expert Perspectives on Cardiac Baseline and Surveillance Testing in Immunotherapy Recipients
EP: 14.Corticosteroid Treatment Challenges in Patients with Immunotherapy-Related Toxicities
EP: 15.Forward Outlook and Clinical Insights in Melanoma Treatment
This is a video synopsis/summary of an OncLive Insights® involving Afreen Shariff, MD, MBBS; Javid Moslehi, MD; and Nikhil Khushalani, MD.
Khushalani notes increased use of various immunotherapy combinations for metastatic or neoadjuvant melanoma, raising concerns for subtle adrenal insufficiency, which is still common. Shariff highlights the importance of maintaining a high suspicion based on subjective fatigue severity/progression and objective trends in weight, blood pressure, and electrolyte level to determine whether laboratory tests are needed. Recognizing adrenal crisis signs preoperatively also matters.
On endocrinopathies, Shariff stresses that they are chronic, so although patients can safely continue immunotherapy, hormone replacement is likely indefinite. She concludes that pretreatment counseling on quality-of-life impacts can help patients understand long-term toxicities such as endocrine dysfunction vs solely emphasizing acute risks when initially consenting.
Video synopsis is AI generated and reviewed by OncLive® editorial staff.
